Therapeutic cancer vaccination is an attractive strategy because it induces T cells of the immune system to recognize and kill tumour cells in cancer patients. However, it remains difficult to generate large numbers of T cells that can recognize the antigens on cancer cells using conventional vaccine carrier systems
1,2. Here we show that
α-Al
2O
3 nanoparticles can act as an antigen carrier to reduce the amount of antigen required to activate T cells
in vitro and
in vivo. We found that
α-Al
2O
3 nanoparticles delivered antigens to autophagosomes in dendritic cells, which then presented the antigens to T cells through autophagy. Immunization of mice with
α-Al
2O
3 nanoparticles that are conjugated to either a model tumour antigen or autophagosomes derived from tumour cells resulted in tumour regression. These results suggest that
α-Al
2O
3 nanoparticles may be a promising adjuvant in the development of therapeutic cancer vaccines.